It is accepted practice that the carriers of truncating variants in CHEK2 are offered at least “moderate” risk screening, with annual mammograms starting from the age of 40 and continuing until the age of 50, with screening thereafter as part of the national breast cancer screening programme. The gene discussed is CHEK2; the disease is breast carcinoma.